- Home
- PRPO vs KZIA Comparison
PRPO vs KZIA Comparison
Compare PRPO & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRPO | KZIA |
|---|---|---|
| Founded | N/A | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.0M | 186.7M |
| IPO Year | 2000 | 2002 |
Fundamental Metrics
Financial Performance| Metric | PRPO | KZIA |
|---|---|---|
| Price | $23.21 | $8.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $28.36 |
| AVG Volume (30 Days) | 84.8K | ★ 277.8K |
| Earning Date | 11-13-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.15 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $24,049,000.00 | N/A |
| Revenue This Year | $233.72 | N/A |
| Revenue Next Year | $22.61 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 29.77 | N/A |
| 52 Week Low | $16.40 | $4.86 |
| 52 Week High | $33.63 | $17.40 |
Technical Indicators
Market Signals| Indicator | PRPO | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 40.20 | 32.99 |
| Support Level | $22.09 | $5.15 |
| Resistance Level | $24.95 | $14.85 |
| Average True Range (ATR) | 1.18 | 0.64 |
| MACD | -0.11 | 0.01 |
| Stochastic Oscillator | 18.10 | 7.47 |
Price Performance
Historical ComparisonAbout PRPO Precipio Inc.
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.